• Bleb placement change for subretinal gene therapy may prevent guttering

    1 month ago - By Healio

    WAILEA, Hawaii - Retinal pigmentary changes were seen in 67% of patients in the phase 1/2 safety study of RGX-314, a gene therapy delivered subretinally for the treatment of AMD.
    One case was considered severe, and location of the bleb placement may be related.
    “Pigmentary change is something that's definitely been noted in a dose-dependent fashion, suggesting that it's not just the bleb mechanical effect,” Allen C. Ho, MD, said at Retina 2021.
    Even so, bleb location could be a factor in the one severe case. Initially, blebs were placed superiorly, and in the one
    Read more ...